Clinical trial Recruiting at 2 sites Interventional Ages 55 and up

Light therapy for patients with Alzheimer's disease

Official title: Phase 2 - The Use of Rhythmic Light Therapy to Entrain Gamma Oscillations and the Circadian System in Patients With Alzheimer's Disease

Run by Icahn School of Medicine at Mount Sinai · NCT05016219 · Data updated 2026-11-12

This study is testing if special blue light therapy can help improve sleep and thinking skills in people with mild Alzheimer's disease and mild cognitive impairment.

Quick facts

Study typeInterventional
Ages55 Years and up
SexAll
Enrollment120 (estimated)
SponsorIcahn School of Medicine at Mount Sinai
Academic / other
Locations2 sites (Menands, New York and 1 other locations)
StatusRecruiting
StartedAugust 22, 2023
Main results expectedMarch 31, 2027
Study endsJuly 31, 2027
Registry record updatedMay 29, 2026
Trial IDNCT05016219 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are individuals diagnosed with mild cognitive impairment or mild Alzheimer's disease who also experience sleep disturbances.

Probably not a fit

Patients taking sleep medications or those with severe sleep disorders may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of rhythmic light therapy on patients with mild cognitive impairment and mild Alzheimer's disease. Participants will be randomly assigned to one of four groups to experience different lighting conditions, including both active and placebo light treatments. The intervention involves exposure to narrowband blue light designed to stimulate circadian rhythms, compared to a placebo red light. Assessments will be conducted weekly over an 8-week period to evaluate cognitive function and sleep quality.

Why it matters

Potential benefit: If successful, this therapy could improve cognitive function and sleep quality in patients with Alzheimer's disease.

How similar studies have gone: Other studies have shown promise with light therapy approaches for cognitive and sleep-related issues, suggesting potential for success in this novel application.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Participants must be diagnosed with mild cognitive impairment or mild Alzheimer's disease, as defined by a Montreal Cognitive Assessment score between 17 and 25;
* Have sleep disturbance indicated by a score \>5 on the Pittsburgh Sleep Quality Index
* Participants must reside in their homes, independent living, or assisted living facilities

Exclusion Criteria:

* Participants taking sleep medication
* Residence in a skilled nursing facility or long-term care
* Obstructing cataracts, macular degeneration, and blindness
* Severe sleep apnea or restless leg syndrome
* History of severe epilepsy

Where it's running

  • Light and Health Research Center
    Menands, New York, United States
    Recruiting
  • Icahn School of Medicine at Mount Sinai
    New York, New York, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.